1. DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study. (30th January 2023) Authors: Danese, S; Abreu, M T; Wolf, D C; Canavan, J B; Jain, A; Wu, H; Petersen, A; Charles, L; Panaccione, R; Afzali, A Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP39 Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study. (30th January 2023) Authors: Vermeire, S; Dignass, A; Colombel, J F; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Rubin, D T; Regueiro, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients. (30th January 2023) Authors: Dignass, A; Regueiro, M; Colombel, J F; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Vermeire, S; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOP52 Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis. (25th January 2019) Authors: Sandborn, W J; Sands, B; Kobayashi, T; Tuttle, J; Schmitz, J; Durante, M; Higgs, R; Canavan, J B; Siegel, R; Ferrante, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S059 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis. (25th January 2019) Authors: D'Haens, G Geert R; Sandborn, W J; Ferrante, M; Bhandari, B R; Berliba, E; Hibi, T; Tuttle, J; Canavan, J B; Friedrich, S; Durante, M; Arora, V; Feagan, B Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S026 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis. (30th January 2023) Authors: Sands, B E; Jain, A; Ahmad, H A; Osterman, M; Memaj, A; Canavan, J B; Axelrad, J E Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i507 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension. (30th January 2023) Authors: Panaccione, R; Danese, S; Wolf, D C; Canavan, J B; Jain, A; Wu, H; Petersen, A; Charles, L; Afzali, A; Abreu, M T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis. (30th January 2023) Authors: Panaccione, R; Danese, S; Wolf, D C; Canavan, J B; Jain, A; Wu, H; Petersen, A; Afzali, A; Abreu, M T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P585 Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study. (30th January 2023) Authors: Vermeire, S; Abraham, B; Bressler, B; Reinisch, W; Jain, A; Memaj, A; Akukwe, L; Liu, W J; Osterman, M; Canavan, J B; Sands, B E Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i713 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P609 Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study. (30th January 2023) Authors: Colombel, J F; Rubin, D T; Vermeire, S; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Dignass, A; Regueiro, R Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i738 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗